Myelodysplastic Syndromes (MDS)

Jason Harold Mendler, MD, PhD, Assistant Professor of Oncology, received his bachelor's degree, Summa Cum Laude, from Washington University in St. Louis, Missouri. He then went on to earn his PhD in Genetics and his medical degree at the University of Rochester School of Medicine and Dentistry in Rochester, New York. Prior to joining Wilmot Cancer Center, Dr. Mendler completed his residency at and served as chief resident of the University of Rochester Medical Center, Department of Medicine. Most recently, he completed a clinical fellowship in oncology at Ohio State University Medical Center

Dr. Austin Kulasekararaj is a hematologist at King’s College Hospital, London. He has trained and worked at King's since 2004, undertaking research in molecular pathogenesis of MDS and aplastic anemia. He specializes in bone marrow failures, myeloid malignancies, and allogeneic bone marrow transplantation. Dr. Kulasekararaj also leads the King's PNH Centre, which is one of two NHS England-commissioned highly specialized services for PNH.

Anthony M. Hunter, MD, is an Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. A hematologist, Dr. Hunter specializes in treating patients with leukemia and other myeloid malignancies including myeloproliferative neoplasms, myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Dr. Hunter holds professional memberships with American Society of Clinical Oncology, American Society of Hematology, and Society of Hematologic Oncology. Dr. Hunter received his Medical Degree from Medical College of Wisconsin in